Met Life Investment Management, LLC 89bio, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 45,232 shares of ETNB stock, worth $376,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,232
Previous 44,775
1.02%
Holding current value
$376,782
Previous $358,000
6.7%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$126 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$118 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$66.6 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$61.5 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$58.4 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $387M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...